1099 related articles for article (PubMed ID: 28666726)
1. Redox-sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models.
Chi Y; Yin X; Sun K; Feng S; Liu J; Chen D; Guo C; Wu Z
J Control Release; 2017 Sep; 261():113-125. PubMed ID: 28666726
[TBL] [Abstract][Full Text] [Related]
2. Chitooligosaccharides Modified Reduction-Sensitive Liposomes: Enhanced Cytoplasmic Drug Delivery and Osteosarcomas-Tumor Inhibition in Animal Models.
Yin X; Chi Y; Guo C; Feng S; Liu J; Sun K; Wu Z
Pharm Res; 2017 Oct; 34(10):2172-2184. PubMed ID: 28726003
[TBL] [Abstract][Full Text] [Related]
3. Estrogen-functionalized liposomes grafted with glutathione-responsive sheddable chotooligosaccharides for the therapy of osteosarcoma.
Yin X; Feng S; Chi Y; Liu J; Sun K; Guo C; Wu Z
Drug Deliv; 2018 Nov; 25(1):900-908. PubMed ID: 29644882
[TBL] [Abstract][Full Text] [Related]
4. Engineering of Bone- and CD44-Dual-Targeting Redox-Sensitive Liposomes for the Treatment of Orthotopic Osteosarcoma.
Feng S; Wu ZX; Zhao Z; Liu J; Sun K; Guo C; Wang H; Wu Z
ACS Appl Mater Interfaces; 2019 Feb; 11(7):7357-7368. PubMed ID: 30682240
[TBL] [Abstract][Full Text] [Related]
5. GE11 peptide modified and reduction-responsive hyaluronic acid-based nanoparticles induced higher efficacy of doxorubicin for breast carcinoma therapy.
Hu D; Mezghrani O; Zhang L; Chen Y; Ke X; Ci T
Int J Nanomedicine; 2016; 11():5125-5147. PubMed ID: 27785019
[TBL] [Abstract][Full Text] [Related]
6. Reduction-sensitive CD44 receptor-targeted hyaluronic acid derivative micelles for doxorubicin delivery.
Yang Y; Zhao Y; Lan J; Kang Y; Zhang T; Ding Y; Zhang X; Lu L
Int J Nanomedicine; 2018; 13():4361-4378. PubMed ID: 30100720
[TBL] [Abstract][Full Text] [Related]
7. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
[TBL] [Abstract][Full Text] [Related]
8. Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts.
Gazzano E; Buondonno I; Marengo A; Rolando B; Chegaev K; Kopecka J; Saponara S; Sorge M; Hattinger CM; Gasco A; Fruttero R; Brancaccio M; Serra M; Stella B; Fattal E; Arpicco S; Riganti C
Cancer Lett; 2019 Aug; 456():29-39. PubMed ID: 31047947
[TBL] [Abstract][Full Text] [Related]
9. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
[TBL] [Abstract][Full Text] [Related]
10. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
[TBL] [Abstract][Full Text] [Related]
11. EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment.
Haghiralsadat F; Amoabediny G; Naderinezhad S; Nazmi K; De Boer JP; Zandieh-Doulabi B; Forouzanfar T; Helder MN
Pharm Res; 2017 Dec; 34(12):2891-2900. PubMed ID: 29110283
[TBL] [Abstract][Full Text] [Related]
12. CD44-specific nanoparticles for redox-triggered reactive oxygen species production and doxorubicin release.
Lin CW; Lu KY; Wang SY; Sung HW; Mi FL
Acta Biomater; 2016 Apr; 35():280-92. PubMed ID: 26853764
[TBL] [Abstract][Full Text] [Related]
13. A novel redox-sensitive system based on single-walled carbon nanotubes for chemo-photothermal therapy and magnetic resonance imaging.
Hou L; Yang X; Ren J; Wang Y; Zhang H; Feng Q; Shi Y; Shan X; Yuan Y; Zhang Z
Int J Nanomedicine; 2016; 11():607-24. PubMed ID: 26917960
[TBL] [Abstract][Full Text] [Related]
14. Free Adriamycin-Loaded pH/Reduction Dual-Responsive Hyaluronic Acid-Adriamycin Prodrug Micelles for Efficient Cancer Therapy.
Yin T; Wang Y; Chu X; Fu Y; Wang L; Zhou J; Tang X; Liu J; Huo M
ACS Appl Mater Interfaces; 2018 Oct; 10(42):35693-35704. PubMed ID: 30259743
[TBL] [Abstract][Full Text] [Related]
15. pH- and GSH-Sensitive Hyaluronic Acid-MP Conjugate Micelles for Intracellular Delivery of Doxorubicin to Colon Cancer Cells and Cancer Stem Cells.
Debele TA; Yu LY; Yang CS; Shen YA; Lo CL
Biomacromolecules; 2018 Sep; 19(9):3725-3737. PubMed ID: 30044910
[TBL] [Abstract][Full Text] [Related]
16. Application of tumor-targeting peptide-decorated polypeptide nanoparticles with doxorubicin to treat osteosarcoma.
Qiu R; Sun D; Bai Y; Li J; Wang L
Drug Deliv; 2020 Nov; 27(1):1704-1717. PubMed ID: 33305647
[TBL] [Abstract][Full Text] [Related]
17. Intracellular delivery and antitumor effects of a redox-responsive polymeric paclitaxel conjugate based on hyaluronic acid.
Yin S; Huai J; Chen X; Yang Y; Zhang X; Gan Y; Wang G; Gu X; Li J
Acta Biomater; 2015 Oct; 26():274-85. PubMed ID: 26300335
[TBL] [Abstract][Full Text] [Related]
18. Hyaluronic acid derivative-coated nanohybrid liposomes for cancer imaging and drug delivery.
Park JH; Cho HJ; Yoon HY; Yoon IS; Ko SH; Shim JS; Cho JH; Park JH; Kim K; Kwon IC; Kim DD
J Control Release; 2014 Jan; 174():98-108. PubMed ID: 24280260
[TBL] [Abstract][Full Text] [Related]
19. cRGD-functionalized reduction-sensitive shell-sheddable biodegradable micelles mediate enhanced doxorubicin delivery to human glioma xenografts in vivo.
Zhu Y; Zhang J; Meng F; Deng C; Cheng R; Feijen J; Zhong Z
J Control Release; 2016 Jul; 233():29-38. PubMed ID: 27178807
[TBL] [Abstract][Full Text] [Related]
20. PEGylated Poly(α-lipoic acid) Loaded with Doxorubicin as a pH and Reduction Dual Responsive Nanomedicine for Breast Cancer Therapy.
Yang H; Shen W; Liu W; Chen L; Zhang P; Xiao C; Chen X
Biomacromolecules; 2018 Nov; 19(11):4492-4503. PubMed ID: 30346147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
